Hematologic and clinical characteristics of EZH2-mutated subjects with PMF stratified according to JAK2V617F mutational status
| . | EZH2 wild-type . | P . | EZH2 mutated . | P . | ||
|---|---|---|---|---|---|---|
| JAK2 . | JAK2 . | |||||
| Wild-type . | V617F . | Wild-type . | V617F . | |||
| N | 143 | 204 | 13 | 9 | ||
| Follow-up, mo (range) n = 354)* | 49.4 (1-340) | 37.9 (1-282) | .020 | 25.7 (8-182) | 30.7 (11-84) | .616 |
| Median age, y, (range) | 55.0 (14-88) | 63.0 (18-90) | .001 | 57.0 (41-81) | 70 (38-90) | .324 |
| Male sex, no. (%) (n = 369)* | 90 (62.9) | 120 (58.8) | .440 | 8 (61.5) | 7 (77.8) | .421 |
| Leukocytes, × 106/L, mean ± SD (n = 354)* | 11.3 ± 13.0 | 13.1 ± 13.5 | .005 | 16.2 ± 11.5 | 22.4 ± 11.1 | .117 |
| Hemoglobin, g/L, mean ± SD (n = 352)* | 109 ± 24 | 118 ± 28 | .002 | 107 ± 22 | 118 ± 14 | .171 |
| Platelet, × 106/L, mean ± SD (n = 355)* | 447.0 ± 403.2 | 408.7 ± 308.0 | .840 | 392.8 ± 255.0 | 422.5 ± 278.6 | .764 |
| Peripheral blast cells, %, mean ± SD (n = 240)* | 1.0 ± 2.6 | 0.5 ± 1.7 | .090 | 1.4 ± 2.4 | 1.8 ± 1.8 | .299 |
| Constitutional symptoms, no. (%) (n = 257)* | 26 (28.3) | 41 (28.1) | .976 | 3 (27.3) | 5 (62.5) | .125 |
| Splenomegaly, no. (%) (n = 352)*† | .747 | .518 | ||||
| 0 | 41 (29.7) | 50 (26.0) | 1 (7.7) | 0 (0.0) | ||
| 1 | 58 (42.0) | 83 (43.2) | 6 (46.2) | 3 (33.3) | ||
| 2 | 39 (28.3) | 59 (30.7) | 6 (46.2) | 6 (66.7) | ||
| Unfavorable karyotype, no. (%) (n = 137) | 8 (12.1) | 10 (16.7) | .466 | 2 (28.6) | 1 (25.0) | .898 |
| JAK2V617F allele burden, %, mean ± SD | 45.9 ± 23.0 | 42.2 ± 22.1 | ||||
| MPL W515L/K, no. (%) (n = 354)* | 12 (8.8) | 1 (0.5) | < .0001 | 0 (0.0) | 0 (0.0) | |
| IWG-MRT score, no. (%) (n = 192)* | .484 | .247 | ||||
| Low | 26 (36.6) | 29 (28.4) | 3 (27.3) | 1 (12.5) | ||
| Int-1 | 14 (19.7) | 30 (29.4) | 4 (36.4) | 1 (12.5) | ||
| Int-2 | 18 (25.4) | 25 (24.5) | 0 (0.0) | 0 (0.0) | ||
| High | 13 (18.3) | 18 (17.6) | 4 (36.4) | 6 (75.0) | ||
| Progression to acute leukemia, no. (%) (n = 345)* | 26 (19.3) | 31 (16.5) | .520 | 6 (46.2) | 1 (11.1) | .083 |
| Death, no. (%) (n = 352)* | 38 (27.7) | 48 (24.7) | .541 | 7 (53.8) | 6 (75.0) | .332 |
| . | EZH2 wild-type . | P . | EZH2 mutated . | P . | ||
|---|---|---|---|---|---|---|
| JAK2 . | JAK2 . | |||||
| Wild-type . | V617F . | Wild-type . | V617F . | |||
| N | 143 | 204 | 13 | 9 | ||
| Follow-up, mo (range) n = 354)* | 49.4 (1-340) | 37.9 (1-282) | .020 | 25.7 (8-182) | 30.7 (11-84) | .616 |
| Median age, y, (range) | 55.0 (14-88) | 63.0 (18-90) | .001 | 57.0 (41-81) | 70 (38-90) | .324 |
| Male sex, no. (%) (n = 369)* | 90 (62.9) | 120 (58.8) | .440 | 8 (61.5) | 7 (77.8) | .421 |
| Leukocytes, × 106/L, mean ± SD (n = 354)* | 11.3 ± 13.0 | 13.1 ± 13.5 | .005 | 16.2 ± 11.5 | 22.4 ± 11.1 | .117 |
| Hemoglobin, g/L, mean ± SD (n = 352)* | 109 ± 24 | 118 ± 28 | .002 | 107 ± 22 | 118 ± 14 | .171 |
| Platelet, × 106/L, mean ± SD (n = 355)* | 447.0 ± 403.2 | 408.7 ± 308.0 | .840 | 392.8 ± 255.0 | 422.5 ± 278.6 | .764 |
| Peripheral blast cells, %, mean ± SD (n = 240)* | 1.0 ± 2.6 | 0.5 ± 1.7 | .090 | 1.4 ± 2.4 | 1.8 ± 1.8 | .299 |
| Constitutional symptoms, no. (%) (n = 257)* | 26 (28.3) | 41 (28.1) | .976 | 3 (27.3) | 5 (62.5) | .125 |
| Splenomegaly, no. (%) (n = 352)*† | .747 | .518 | ||||
| 0 | 41 (29.7) | 50 (26.0) | 1 (7.7) | 0 (0.0) | ||
| 1 | 58 (42.0) | 83 (43.2) | 6 (46.2) | 3 (33.3) | ||
| 2 | 39 (28.3) | 59 (30.7) | 6 (46.2) | 6 (66.7) | ||
| Unfavorable karyotype, no. (%) (n = 137) | 8 (12.1) | 10 (16.7) | .466 | 2 (28.6) | 1 (25.0) | .898 |
| JAK2V617F allele burden, %, mean ± SD | 45.9 ± 23.0 | 42.2 ± 22.1 | ||||
| MPL W515L/K, no. (%) (n = 354)* | 12 (8.8) | 1 (0.5) | < .0001 | 0 (0.0) | 0 (0.0) | |
| IWG-MRT score, no. (%) (n = 192)* | .484 | .247 | ||||
| Low | 26 (36.6) | 29 (28.4) | 3 (27.3) | 1 (12.5) | ||
| Int-1 | 14 (19.7) | 30 (29.4) | 4 (36.4) | 1 (12.5) | ||
| Int-2 | 18 (25.4) | 25 (24.5) | 0 (0.0) | 0 (0.0) | ||
| High | 13 (18.3) | 18 (17.6) | 4 (36.4) | 6 (75.0) | ||
| Progression to acute leukemia, no. (%) (n = 345)* | 26 (19.3) | 31 (16.5) | .520 | 6 (46.2) | 1 (11.1) | .083 |
| Death, no. (%) (n = 352)* | 38 (27.7) | 48 (24.7) | .541 | 7 (53.8) | 6 (75.0) | .332 |